Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Layne Hartnell

Physician Assistant, Medical Mount Vernon, OH Physician Assistant

NPI 1548906209 CMS profile 11417745

112 Harcourt Rd Ste 2, Mount Vernon, OH 43050

Open in the dashboard

General payments

$13,286

717 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Layne Hartnell of Mount Vernon, OH is reported in the CMS Open Payments database as having received $13,286 across 717 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,075 249
2024 General $4,674 284
2023 General $4,200 177
2022 General $336 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Layne Hartnell
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Layne Hartnell were reported at $4,075. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Layne Hartnell Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $336 $185 $55–$649 $149
2023 $4,200 $199 $58–$717 $160
2024 $4,674 $206 $62–$740 $164
2025 $4,075 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $4,054 264 payments
  2. Janssen Pharmaceuticals, Inc $1,795 34 payments
  3. ITI, Inc. $1,145 55 payments
  4. Alkermes, Inc. $896 53 payments
  5. Otsuka America Pharmaceutical, Inc. $748 41 payments
  6. Vanda Pharmaceuticals Inc. $733 41 payments
  7. Teva Pharmaceuticals USA, Inc. $584 38 payments
  8. Supernus Pharmaceuticals, Inc. $504 54 payments
  9. Axsome Therapeutics, Inc. $455 13 payments
  10. Neurocrine Biosciences, Inc. $320 20 payments
  11. Other $2,053 104 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $11,977 711 payments
  2. Travel and Lodging $1,169 3 payments
  3. Education $140 3 payments
Products named General payments · program years 2022–2025
  1. VRAYLAR Neuroscience $3,229 203 payments
  2. SPRAVATO $1,675 28 payments
  3. LYBALVI $860 48 payments
  4. ARISTADA Cns $860 48 payments
  5. ARISTADA Cns $860 48 payments
  6. ARISTADA Cns $860 48 payments
  7. ARISTADA Cns $860 48 payments
  8. VRAYLAR Neuroscience $824 61 payments
  9. CAPLYTA $804 44 payments
  10. FANAPT $733 41 payments
  11. Other $5,587 331 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

413

Median for Physician Assistant: 241

Drug cost

$89,144

Median for Physician Assistant: $4,110

Branded share of claims

24.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 20 $44,171
Vraylar Cariprazine Hcl Brand 11 $17,192
Lybalvi Olanzapine/Samidorphan Malate Brand 11 $16,538
Vyvanse Lisdexamfetamine Dimesylate Brand 13 $4,832
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 26 $2,903
Olanzapine Generic 15 $622
Duloxetine Hcl Generic 19 $462
Gabapentin Generic 44 $380
Lithium Carbonate Er Lithium Carbonate Brand 20 $351
Quetiapine Fumarate Generic 31 $267

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$20,726

Medicare's payments for the services billed

Medicare patients

26

Average age 64

Services billed

386

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 62%
High blood pressure 42%
Arthritis 42%
Atrial fibrillation 0%
Chronic kidney disease 0%
COPD 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $1,821
$1,821 11 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $372
  • Lundbeck LLC $13
$385 — —
CAPLYTA
  • ITI, Inc. $331
$331 20 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $235
$235 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $233
$233 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

717 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record